Table 2 NGS mutation analysis in the patient primary tumour versus MUG-Myx2a and MUG-Myx2b cell lines.
From: Establishment of a novel cellular model for myxofibrosarcoma heterogeneity
Patient tissue MAF % | MUG- Myx2a MAF % | MUG- Myx2b MAF % | Gene symbol | Mutation | Transcript | Genomic coordinate | SIFT score |
|---|---|---|---|---|---|---|---|
62.25 | 59.75 | 54.18 | FGFR3 | p.F386L | NM_001163213 | Chr 4, 1806131 | 0.47 |
60.91 | 68.67 | 73.38 | KIT | p.M541L | NM_000222 | Chr 4, 55593464 | 0.6 |
58.68 | 69.24 | 50.91 | KDR | p.Q472H | NM_002253 | Chr 4, 55972974 | 0.35 |
0 | 24.56 | 0 | PTEN | p.R173H | NM_000314 | Chr 10, 89711900 | 0 |
73.88 | 100 | 100 | TP53 | p.R213Q | NM_000546 | Chr 17, 7578211 | 0 |
